Therapeutic Asset Ratings
137 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Breast Neoplasms
Merck Sharp & Dohme LLC
P4
BB
(70)
Docetaxel
Breast Neoplasms
Universitas Airlangga
P4
BB
(70)
EXEMESTANE
Breast Neoplasms
Fujian Cancer Hospital
P4
BB
(70)
Inno-206
Breast Neoplasms
Merck Sharp & Dohme LLC
P4
BB
(70)
Letrozole
Breast Neoplasms
Fujian Cancer Hospital
P4
BB
(70)
TAMOXIFEN
Breast Neoplasms
Eli Lilly and Company
P3
BB
(70)
Epirubicin
Breast Neoplasms
Universitas Airlangga
P4
BB
(69)
ERIBULIN MONOMETHANESULFONATE
Breast Neoplasms
Fudan University
P4
BB
(69)
Palbociclib
Breast Neoplasms
Eli Lilly and Company
P4
BB
(69)
Arimidex
Breast Neoplasms
Fujian Cancer Hospital
P4
BB
(68)
Capecitabine
Breast Neoplasms
Kristina A. Fanucci
P4
BB
(68)
TRASTUZUMAB
Breast Neoplasms
Merck Sharp & Dohme LLC
P3
BB
(68)
FLUOROURACILUM
Breast Neoplasms
Rutgers, The State University of New Jersey
P4
BB
(67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Breast Neoplasms
Merck Sharp & Dohme LLC
P4
BB
(67)
ROPIVACAINE
Breast Neoplasms
Fudan University
P4
BB
(67)
FULVESTRANT
Breast Neoplasms
Eli Lilly and Company
P4
BB
(66)
Carboplatin
Breast Neoplasms
BioNTech SE
P3
BB
(66)
Eloxatin
Breast Neoplasms
Kristina A. Fanucci
P3
BB
(66)
Abemaciclib
Breast Neoplasms
Eli Lilly and Company
P4
BB
(64)
Zoladex
Breast Neoplasms
Eli Lilly and Company
P4
BB
(64)
Eribulin
Breast Neoplasms
BioNTech SE
P4
B
(63)
LEUPROLIDE
Breast Neoplasms
Eli Lilly and Company
P4
B
(63)
Ribociclib
Breast Neoplasms
Eli Lilly and Company
P4
B
(63)
Olaparib
Breast Neoplasms
Merck Sharp & Dohme LLC
P3
B
(62)
Vinorelbine
Breast Neoplasms
Sun Yat-sen University
P3
B
(62)
Showing 1 to 25 of 137 assets
Previous
Page 1 of 6
Next